Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2022-06-14
Target enrollment:
Participant gender:
Summary
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD)
study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene
3) bispecific antibody, for participants with advanced and/or metastatic solid tumors. This
study aims to establish the maximum tolerated dose (MTD) and/or define the recommended phase
2 dose (RP2D) based on the safety, tolerability, pharmacokinetic (PK) and/or pharmacodynamic
(PD) profile of RO7247669, and to evaluate preliminary anti-tumor activity in participants
with solid tumors. An expansion part of the study is planned to enroll tumor-specific cohorts
to evaluate anti-tumor activity of the MTD and/or RP2D of RO7247669 and to confirm safety and
tolerability in participants with selected tumor types.